Literature DB >> 12110228

Virus-based vectors for human vaccine applications.

John M Polo1, Thomas W Dubensky.   

Abstract

Vaccinology has experienced a dramatic resurgence recently, as traditional methodologies of using attenuated live pathogens or inactivated whole pathogens have been either ineffective or are not an acceptable risk for several disease targets, including HIV and Hepatitis C. Gene-based vaccines can stimulate potent humoral and cellular immune responses, and viral vectors might be an efficient strategy for both delivery of antigen-encoding genes, as well as facilitating and enhancing antigen presentation. Vectors derived from diverse viruses with distinct tropism and gene expression strategies have been developed, and are being evaluated in preclinical and clinical vaccine studies. Virus-based vaccines represent a promising approach for vaccines against infectious and malignant disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110228     DOI: 10.1016/s1359-6446(02)02324-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  13 in total

1.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.

Authors:  Muhammad Faheem; Ummar Raheel; Muhammad Nasir Riaz; Naghmana Kanwal; Farakh Javed; Najam us Sahar Sadaf Zaidi; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2010-11-24       Impact factor: 2.316

3.  Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.

Authors:  Chien-Hsiung Pan; Alexandra Valsamakis; Teresa Colella; Nitya Nair; Robert J Adams; Fernando P Polack; Catherine E Greer; Silvia Perri; John M Polo; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

4.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 5.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

6.  Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.

Authors:  Marcela F Pasetti; Eileen M Barry; Genevieve Losonsky; Mahender Singh; Sandra M Medina-Moreno; John M Polo; Jeffrey Ulmer; Harriet Robinson; Marcelo B Sztein; Myron M Levine
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 7.  T cell vaccinology: exploring the known unknowns.

Authors:  Matt A Burchill; Beth A Tamburini; Nathan D Pennock; Jason T White; Jonathan S Kurche; Ross M Kedl
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

8.  An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.

Authors:  E S Gabitzsch; Y Xu; S Balcaitis; J P Balint; F R Jones
Journal:  Cancer Gene Ther       Date:  2011-01-14       Impact factor: 5.987

9.  Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.

Authors:  Xiaoyan Wang; Jian-Ping Wang; Xiao-Mei Rao; Janet E Price; Heshan S Zhou; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2005-05-23       Impact factor: 6.466

10.  Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.

Authors:  Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-11-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.